Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Announces New Additions to Senior Leadership Team
Daniel L. Cohen , global public policy and government relations leader, appointed Executive Vice President, Government and Public Relations Rene A. Braeckman , Ph.D., clinical development expert, appointed Vice President, Clinical Development CORALVILLE, Iowa , April 19, 2016 (GLOBE NEWSWIRE) --
Toggle Summary KemPharm Receives Clearance from FDA to Initiate Human Clinical Trials of KP511, an Investigational Prodrug of Hydromorphone
KemPharm plans to develop KP511 as an abuse-deterrent, extended-release product CORALVILLE, Iowa , March 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that its Investigational New Drug (IND) application for KP511, KemPharm’s prodrug of hydromorphone, has been accepted by
Toggle Summary KemPharm Receives NDA User Fee Waiver from FDA
CORALVILLE, Iowa , March 24, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration ( FDA ) has granted a fee waiver and has
Toggle Summary KemPharm Announces FDA Advisory Committee Meeting For Lead Abuse-Deterrent Drug Candidate KP201/APAP
CORALVILLE, Iowa , March 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that a joint meeting of the Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S.
Toggle Summary KemPharm, Inc. Reports Q4 and Year End 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights : Submitted New Drug Application (NDA) under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act for KP201/APAP to the U.S.
Toggle Summary KemPharm Files IND for KP511, an Investigational Prodrug of Hydromorphone
CORALVILLE, Iowa , March 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) requesting clearance to begin human clinical trials of KP511, KemPharm’s prodrug of
Toggle Summary FDA Grants Priority Review to KemPharm for KP201/APAP NDA
If Approved, KP201/APAP Could Become the First Immediate-Release Hydrocodone Combination Product With Abuse-Deterrent Properties CORALVILLE, Iowa , Feb. 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) today announced that the New Drug Application (NDA) for KP201/APAP, its investigational
Toggle Summary KemPharm Announces Closing of $86.25 Million 5.50% Senior Convertible Notes Due 2021
CORALVILLE, Iowa , Feb. 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH) announced today the closing of $86.25 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under
Toggle Summary KemPharm Announces Pricing of $75.0 Million 5.50% Senior Convertible Notes Due 2021
CORALVILLE, Iowa , Feb. 04, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH)  announced today the pricing of $75.0 million aggregate principal amount of 5.50% senior convertible notes due 2021 (the “notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under
Toggle Summary KemPharm Added to NASDAQ Biotechnology Index
CORALVILLE, Iowa , Jan. 07, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that the company was selected for addition to the NASDAQ Biotechnology Index
Toggle Summary KemPharm, Inc. Expands Pain Therapy Pipeline With Discovery of KP746
Novel Prodrug of Oxymorphone Adds New Asset to KemPharm’s Advancing Abuse-Deterrent Product Portfolio CORALVILLE, Iowa , Dec. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary
Toggle Summary KemPharm Submits NDA for KP201/APAP and Requests Priority Review From the FDA
If Approved, KP201/APAP May be the First Immediate Release Hydrocodone Combination Product Candidate for the Treatment of Acute Pain Designed to Address Opioid Abuse and Misuse CORALVILLE, Iowa , Dec. 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), today announced that it has submitted a
Toggle Summary KemPharm, Inc. Reports Q3 2015 Results
Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Completed Human Abuse Liability Program for KP201/APAP , KemPharm's prodrug of hydrocodone (KP201), formulated in combination with acetaminophen (APAP) Reported positive results from
Toggle Summary KemPharm, Inc. Completes Human Abuse Liability Program for KP201/APAP
Positive Results From Second Intranasal Human Abuse Liability Clinical Trial Reaffirm Properties of KP201/APAP Conference Call and Live Audio Webcast Scheduled for Today at 5:00 p.m. ET CORALVILLE, Iowa , Oct. 21, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc.
Toggle Summary KemPharm Enhances U.S. and Global Intellectual Property Estate
KemPharm Receives Patent From the USPTO for Novel Prodrug of Methylphenidate, KP415, Additional USPTO Patent Protection for KP201, and Multiple Ex-US Patents for KP511 and KP303 CORALVILLE, Iowa , Oct. 13, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty
Toggle Summary KemPharm Reports Positive Data Demonstrating Tamper-Resistant Properties of KP201/APAP
Results Indicate That Prodrug Design of KP201/APAP Significantly Hinders Traditional Means of Abuse, Including Extraction, Injection and Smoking CORALVILLE, Iowa , Sept. 30, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the
Toggle Summary KemPharm Expands Its Abuse-Deterrent Opioid Pipeline With New Acetaminophen-Free, Immediate Release Hydrocodone and Immediate Release Oxycodone Prodrug Product Candidates
Provides Updates on Clinical Development Pipeline and Anticipated NDA Filings CORALVILLE, Iowa , Sept. 24, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that
Toggle Summary KemPharm to Highlight the Potential of Prodrugs at the 9th Annual Pain & Migraine Therapeutics Summit
Presentation by Sven Guenther, Ph.D., KemPharm's EVP of Research & Development, to Showcase Prodrugs and the Clinical Progress of KP201/APAP and KP511 CORALVILLE, Iowa , Sept. 23, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in
Toggle Summary KemPharm Data to be Presented at PAINWeek 2015
Posters Highlight Data on Opioid Abuse Prevalence, and the Advantages of Prodrugs and KP201/APAP in Preventing Abuse and Misuse CORALVILLE, Iowa , Sept. 8, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and
Toggle Summary KemPharm, Inc. Announces Positive Data From Intranasal Human Abuse Liability Study of KP201/APAP; Reports Q2 2015 Results
Results from First of Two Intranasal Human Abuse Liability Clinical Studies Indicate KP201 Exhibits Significantly Lower Exposure to Hydrocodone When Administered Intranasally Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development Highlights: Reports